# Clemens Van Blitterswijk

> Clemens Van Blitterswijk is a Series B investor at EQT Life Sciences backing Health Care. See 2 investments, check sizes, portfolio and contact details…

- Type: Angel Investor
- Fund: [EQT Life Sciences](https://shizune.co/investors/profile/life-sciences-partners)
- Location: Enschede, The Netherlands
- Total investments: 2
- Last investment: Sep 2019
- Lead investor: 100%
- Last updated: Aug 2026

Clemens Van Blitterswijk is a Series B investor at EQT Life Sciences in Enschede focused on Health Care and Therapeutics. Clemens Van Blitterswijk is based out of Enschede, Overijssel and currently works as a Professor of Tissue Regeneration for University of Twente. Clemens Van previously worked at ISOTIS as a CEO. Clemens Van Blitterswijk attended the University of Twente. Clemens Van Blitterswijk has been awarded the Jean Leray award.

## Contacts

5 contacts available for Clemens Van Blitterswijk: work email, personal email, work phone, personal phone and socials. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-email/clemens-van-blitterswijk?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 1 | 50% |
| Therapeutics | 1 | 50% |
| Medical Device | 1 | 50% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 1 | 50% |
| Series D | 1 | 50% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Xeltis | A clinical-stage medical device company, Xeltis has developed the most advanced polymer-based restorative devices for cardiovascular treatment. Xeltis’ restorative devices include implantable small diameter blood vessels for hemodialysis vascular access and for coronary artery bypass graft (CABG) surgery and pulmonary heart valves, for whichclinical trials are ongoing. Xeltis was formed through the merger of two Dutch/Swiss university spin-offs. It currently has operations in The Netherlands and in the USA. Xeltis’ investors include venture capital funds EQT Life Sciences, Kurma Partners, VI Partners and Ysios Capital as well as a number of private investors. In 2021, Xeltis secured a €15 million financing from the European Investment Bank and a €15 million funding from the European Innovation Council Accelerator (EIC) set up by the European Commission. | $11.7M | Series D | Sep 06, 2019 | http://xeltis.com/ |
| Xeltis | A clinical-stage medical device company, Xeltis has developed the most advanced polymer-based restorative devices for cardiovascular treatment. Xeltis’ restorative devices include implantable small diameter blood vessels for hemodialysis vascular access and for coronary artery bypass graft (CABG) surgery and pulmonary heart valves, for whichclinical trials are ongoing. Xeltis was formed through the merger of two Dutch/Swiss university spin-offs. It currently has operations in The Netherlands and in the USA. Xeltis’ investors include venture capital funds EQT Life Sciences, Kurma Partners, VI Partners and Ysios Capital as well as a number of private investors. In 2021, Xeltis secured a €15 million financing from the European Investment Bank and a €15 million funding from the European Innovation Council Accelerator (EIC) set up by the European Commission. | $29.6M | Series B | Dec 02, 2014 | http://xeltis.com/ |

2 of 2 investments shown.

## Co-investors
- [Kurma Partners](https://shizune.co/investors/profile/kurma-life-science-partners) — VC Fund, 1 deal together
- [VI Partners](https://shizune.co/investors/profile/vi-partners) — VC Fund, 1 deal together

## About EQT Life Sciences

VC Fund · Amsterdam, The Netherlands

EQT life science develops innovative medicines, devices, and tools to address the single important thing that matters to the preservation of health. The organization believes that such opportunities add value to all stakeholders.

5 contacts available at EQT Life Sciences.

| Name | Title | Profile |
| --- | --- | --- |
| Christoph Broja | Partner | https://shizune.co/investors/profile/christoph-broja-c9a3 |
| Fouad Azzam | General Partner | https://shizune.co/investors/profile/fouad-azzam |
| Joachim Rothe | General Partner | https://shizune.co/investors/profile/joachim-rothe |
| Clemens Van Blitterswijk | Founder of LSP Health Economics Fund | https://shizune.co/investors/profile/clemens-van-blitterswijk |
| Daniela Begolo | Managing Director | https://shizune.co/investors/profile/daniela-begolo |

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Clemens Van Blitterswijk invest in?

Clemens Van Blitterswijk invests primarily in Health Care, Therapeutics and Medical Device startups, most often at Series B and Series D stage. Most of the 2 investments tracked by Shizune back companies in Switzerland. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Clemens Van Blitterswijk?

For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### When did Clemens Van Blitterswijk last invest?

The most recent investment recorded for Clemens Van Blitterswijk closed in Sep 2019. Shizune tracks 2 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co